As of 2025-05-16, the Intrinsic Value of BioLine RX Ltd (BLRX.TA) is 0.40 USD. This BLRX.TA valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1.90 USD, the upside of BioLine RX Ltd is -78.80%.
The range of the Intrinsic Value is 0.28 - 0.93 USD
Based on its market price of 1.90 USD and our intrinsic valuation, BioLine RX Ltd (BLRX.TA) is overvalued by 78.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 0.28 - 0.93 | 0.40 | -78.8% |
| DCF (Growth 10y) | 0.65 - 3.01 | 1.06 | -44.0% |
| DCF (EBITDA 5y) | 0.37 - 0.56 | 0.45 | -76.1% |
| DCF (EBITDA 10y) | 0.69 - 1.31 | 0.94 | -50.4% |
| Fair Value | -2.07 - -2.07 | -2.07 | -208.69% |
| P/E | (7.02) - (11.93) | (7.74) | -507.6% |
| EV/EBITDA | 1.79 - 2.92 | 2.19 | 15.1% |
| EPV | (6.82) - (12.94) | (9.88) | -620.0% |
| DDM - Stable | (3.62) - (12.17) | (7.90) | -515.6% |
| DDM - Multi | (2.32) - (6.24) | (3.41) | -279.2% |
| Market Cap (mil) | 42.42 |
| Beta | 0.44 |
| Outstanding shares (mil) | 22.33 |
| Enterprise Value (mil) | 47.02 |
| Market risk premium | 5.63% |
| Cost of Equity | 9.52% |
| Cost of Debt | 18.53% |
| WACC | 10.76% |